ArticleEukaryotic cell2015
Development of the CRISPR/Cas9 System for Targeted Gene Disruption in Aspergillus fumigatus.
Article in Eukaryotic cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 247 citations in OpenAlex.
- OmniEdit: A unified CRISPR/Cas9 platform for precise genome engineering and strain optimization of theSynthetic and systems biotechnology · 2026Article
- Intracellular pathogen manipulation of ER-phagy: direct receptor targeting and indirect pathway perturbation.Medical microbiology and immunology · 2026Review
- CRISPR-Cas9-mediated targeted gene deletion inMicrobiology spectrum · 2026Article
- Advancements in CRISPR-Cas Systems for Genome Editing towards Eradication of Human Microbial Pathogens.Molecular biotechnology · 2026Review
- Editing gliA, gliP and gliZ of Aspergillus fumigatus Using CRISPR/Cas System Renders Fungus Incapable to Produce Gliotoxin.Molecular biotechnology · 2026Article
- CRISPR/Cas systems in fungal biotechnology: advancing high-value metabolite synthesis for industrial and food security applications.Archives of microbiology · 2026Review
- Refining the Study of Endophytic Fungi: Best Practices in Antibacterial Research.Current microbiology · 2026Review
- Functionally redundant Rho GTPases Cdc42 and RacA regulate aflatoxin synthesis and pathogenicity inMycology · 2026Article
- CRISPR-Cas9 Gene Editing inBiology · 2025Review
- Optimization of the Genome Editing CRISPR-Cas9 Technology in Scedosporium apiospermum.Mycopathologia · 2025Article
- Simultaneous multigene integration in Aspergillus fumigatus using CRISPR/Cas9 and endogenous counter-selectable markers.Journal of biological engineering · 2025Article
- CRISPR/Cas9-assisted gene editing reveals that EgPKS, a polyketide synthase, is required for the biosynthesis of preussomerins in Edenia gomezpompae SV2.World journal of microbiology & biotechnology · 2025Article
- CRISPR/Cas9 mediated targeted knock-in of eglA gene to improve endoglucanase activity of Aspergillus fumigatus LMB-35Aa.Scientific reports · 2024Article
- Genome editing tools based improved applications in macrofungi.Molecular biology reports · 2024Review
- Vitamin B5 metabolism is essential for vacuolar and mitochondrial functions and drug detoxification in fungi.Communications biology · 2024Article
- Advanced genetic techniques in fungal pathogen research.mSphere · 2024Review
- Utilization of CRISPR-Cas genome editing technology in filamentous fungi: function and advancement potentiality.Frontiers in microbiology · 2024Review
- Article
- CRISPR-Cas9 System: A Prospective Pathway toward Combatting Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2023Review
- A Simple CRISPR/Cas9 System for Efficiently Targeting Genes of Aspergillus SectionMicrobiology spectrum · 2023Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Low rates of homologous recombination have broadly encumbered genetic studies in the fungal pathogen Aspergillus fumigatus. The CRISPR/Cas9 system of bacteria has recently been developed for targeted mutagenesis of eukaryotic genomes with high efficiency and, importantly, through a mechanism independent of homologous repair machinery. As this new technology has not been developed for use in A. fumigatus, we sought to test its feasibility for targeted gene disruption in this organism. As a proof of principle, we first demonstrated that CRISPR/Cas9 can indeed be used for high-efficiency (25 to 53%) targeting of the A. fumigatus polyketide synthase gene (pksP), as evidenced by the generation of colorless (albino) mutants harboring the expected genomic alteration. We further demonstrated that the constitutive expression of the Cas9 nuclease by itself is not deleterious to A. fumigatus growth or virulence, thus making the CRISPR system compatible with studies involved in pathogenesis. Taken together, these data demonstrate that CRISPR can be utilized for loss-of-function studies in A. fumigatus and has the potential to bolster the genetic toolbox for this important pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.